RELATED CONTENT
September 17, 2009 - Lantheus Medical Imaging Inc. today announced the initiation of a Phase 1 clinical study to assess the safety, dosimetry and tolerability of LMI1195, a novel F-18 small molecule tracer for imaging cardiac neuronal function, in healthy subjects, undergoing positron emission tomography (PET) imaging.
September 16, 2009 
August 14, 2009 - Lantheus Medical Imaging will continue to allocate its Mo-99 supply to serve as many people as possible, said the company today in response to the statement issued by AECL regarding the extended shutdown of the NRU reactor Aug. 12.
August 14, 2009 
July 9, 2009 - The U.S.
July 08, 2009 
June 15, 2009 - Lantheus Medical Imaging Inc. today said it finalized an arrangement with the Australian Nuclear Science and Technology Organization (ANSTO) to receive the nuclear imaging radiotracer component molybdenum-99 (Mo-99) produced from low-enriched uranium (LEU) targets in ANSTO’s new OPAL reactor.
June 15, 2009 June 13, 2009 - Lantheus will be the first company to be able to offer Technetium-99 (Tc99m) derived from LEU to the U.S. market.
June 13, 2009 June 4, 2009 - Lantheus Medical Imaging Inc. said today the company’s leading imaging agent, Cardiolite (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), was used in a recently completed five-year study examining appropriate treatment regimens for patients with type 2 diabetes and coronary artery disease.
June 04, 2009 
May 28, 2009 - Lantheus Medical Imaging Inc. has completed patient enrollment of CaRES (Contrast Echocardiography REgistry for Safety Surveillance), the first, multicenter Phase IV observational registry that evaluates the use of ultrasound imaging agents in routine clinical practice. The 1,060 patients who were enrolled at 15 sites in the U.S.
May 28, 2009 
May 20, 2009 – Lantheus Medical Imaging Inc. has signed an agreement with NTP Radioisotopes (Pty) Ltd., a subsidiary of the South African Nuclear Energy Corp. (NECSA), to manufacture and supply Lantheus with an ongoing volume of molybdenum-99 (Mo-99), a key isotope used in medical imaging procedures.
May 20, 2009 April 7, 2009 - Lantheus Medical Imaging Inc. has acquired the U.S., Canadian and Australian rights to MS-325 (formerly marketed as VASOVIST, gadofosveset trisodium, by Bayer Schering Pharma) from EPIX Pharmaceuticals.
April 06, 2009 
March 31, 2009 – Lantheus Medical Imaging Inc.
March 31, 2009